Journal Mobile Options
Table of Contents
Vol. 79, No. 1, 2004
Issue release date: January 2004
Neuroendocrinology 2004;79:34–42

Modulation of Neuroendocrine Response and Non-Verbal Behavior during Psychosocial Stress in Healthy Volunteers by the Glutamate Release-Inhibiting Drug Lamotrigine

Makatsori A. · Duncko R. · Moncek F. · Loder I. · Katina S. · Jezova D.
aLaboratory of Pharmacological Neuroendocrinology, Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovakia; bInstitute of Adaptive and Spaceflight Physiology, Graz, Austria, and cDepartment of Probability and Mathematical Statistics, Faculty of Mathematics, Physics and CS, Comenius University, Bratislava, Slovakia

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The present work was aimed at verifying the following hypotheses: (a) lamotrigine, a drug used to treat mood disorders, affects regulation of stress hormone release in humans, and (b) non-verbal behavior during mental stress situations (public speech) is related to hormonal responses. To achieve these aims, we performed a controlled, double-blind study investigating hormonal responses and non-verbal behavior during public speech in healthy subjects with placebo or lamotrigine (300 mg per os) pretreatment. The stress procedure was performed in 19 young healthy males 5 h following drug or placebo administration. Data were obtained from cardiovascular monitoring, blood and saliva samples, as well as the video-recorded speech. Pre-stress hormone levels were not affected by lamotrigine treatment. Lamotrigine significantly inhibited diastolic blood pressure, growth hormone and cortisol increases during psychosocial stress. In contrast, it potentiated plasma renin activity and aldosterone responses. Non-verbal behavior analysis revealed a correlation between catecholamines and submissive or flight behavior in controls, while between catecholamines and displacement behavior following lamotrigine administration. In conclusion, effects of lamotrigine on hormone release might be of value for its mood-stabilizing action used in the treatment of bipolar disorder. The data are in support of a stimulatory role of glutamate in the control of cortisol and growth hormone release during psychosocial stress in humans; however, further studies using more selective drugs are needed to prove this suggestion. The effects on plasma renin activity and aldosterone release observed seem to be related to other actions of lamotrigine.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Rovensky J, Bakosova J, Koska J, Ksinantova L, Jezova D, Vigas M: Somatotropic, lactotropic and adrenocortical responses to insulin-induced hypoglycemia in patients with rheumatoid arthritis. Ann NY Acad Sci 2002;966:263–270.
  2. Pullinen T, Mero A, Huttunen P, Pakarinen A, Komi PV: Resistance exercise-induced hormonal responses in men, women and pubescent boys. Med Sci Sports Exerc 2002;34:806–813.
  3. Kok FW, Westenberg HG, Thijssen JH, van Ree JM: Endocrine and cardiovascular responses to a series of graded physical and psychological stress stimuli in healthy volunteers. Eur Neuropsychopharmacol 1995;5:515–522.
  4. McCleery JM, Bhagwagar Z, Smith KA, Goodwin GM, Cowen PJ: Modelling a loss event: Effect of imagined bereavement on the hypothalamic-pituitary-adrenal axis. Psychol Med 2000;30:219–223.
  5. Skosnik PD, Chatterton RT Jr, Swisher T, Park S: Modulation of attentional inhibition by norepinephrine and cortisol after psychological stress. Int J Psychophysiol 2000;36:59–68.
  6. Kirschbaum C, Pirke KM, Hellhammer DH: The ‘Trier Social Stress Test’ – A tool for investigating psychobiological stress responses in a laboratory setting. Neuropsychobiology 1993;28:76–81.
  7. Clow A, Patel S, Najafi M, Evans PD, Hucklebridge F: The cortisol response to psychological challenge is preceded by a transient rise in endogenous inhibitor of monoamine oxidase. Life Sci 1997;61:567–575.l
  8. Troisi A: Ethological research in clinical psychiatry: The study of nonverbal behavior during interviews. Neurosci Biobehav Rev 1999;23:905–913.
  9. De Kloet RE: Hormones, brain and stress. Endocr Regul 2003;37:51–68.
  10. Hurley SC: Lamotrigine update and its use in mood disorders. Ann Pharmacother 2002;36:860–873.
  11. Jezova D, Tokarev D, Rusnak M: Endogenous excitatory amino acids are involved in stress-induced adrenocorticotropin and catecholamine release. Neuroendocrinology 1995;62:326–332.
  12. Tokarev D, Jezova D: Effect of central administration of the non-NMDA receptor antagonist DNQX on ACTH and corticosterone release before and during immobilization stress. Methods Find Exp Clin Pharmacol 1997;19:323–328.
  13. Schwendt M, Jezova D: Gene expression of two glutamate receptor subunits in response to repeated stress exposure in rat hippocampus. Cell Mol Neurobiol 2000;20:319–329.
  14. Scaccianoce S, Matrisciano F, Del Bianco P, Caricasole A, Di GG, V, Cappuccio I, Melchiorri D, Battaglia G, Nicoletti F: Endogenous activation of group-II metabotropic glutamate receptors inhibits the hypothalamic-pituitary-adrenocortical axis. Neuropharmacology 2003;44:555–561.
  15. Bradbury MJ, Giracello DR, Chapman DF, Holtz G, Schaffhauser H, Rao SP, Varney MA, Anderson JJ: Metabotropic glutamate receptor 5 antagonist-induced stimulation of hypothalamic-pituitary-adrenal axis activity: Interaction with serotonergic systems. Neuropharmacology 2003;44:562–572.
  16. Kniest A, Wiesenberg C, Weber B, Colla M, Heuser I, Deuschle M: The glutamate antagonist riluzole and its effects upon basal and stress-induced activity of the human hypothalamus-pituitary-adrenocortical system in elderly subjects. Neuropsychobiology 2001;43:91–95.
  17. Goldsmith DR, Wagstaff AJ, Ibbotson T, Perry CM: Lamotrigine: A review of its use in bipolar disorder. Drugs 2003;63:2029–2050.
  18. Jezova D, Kvetnansky R, Kovacs K, Oprsalova Z, Vigas M, Makara GB: Insulin-induced hypoglycemia activates the release of adrenocorticotropin predominantly via central and propranolol insensitive mechanisms. Endocrinology 1987;120:409–415.
  19. Peuler JD, Johnson GA: Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. Life Sci 1977;21:625–636.
  20. Jezova D, Duncko R, Lassanova M, Kriska M, Moncek F: Reduction of rise in blood pressure and cortisol release during stress by Ginkgo biloba extract (EGb 761) in healthy volunteers. J Physiol Pharmacol 2002;53:337–348.
  21. Vajda FJ: Neuroprotection and neurodegenerative disease. J Clin Neurosci 2002;9:4–8.
  22. Farber NB, Jiang XP, Heinkel C, Nemmers B: Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol Psychiatry 2002;7:726–733.
  23. Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, Krystal JH: Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: Support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry 2000;57:270–276.
  24. Brody SA, Geyer MA, Large CH: Lamotrigine prevents ketamine but not amphetamine-induced deficits in prepulse inhibition in mice. Psychopharmacology (Berl) 2003;169:240–246.
  25. Ziegler DR, Herman JP: Local integration of glutamate signaling in the hypothalamic paraventricular region: Regulation of glucocorticoid stress responses. Endocrinology 2000;141:4801–4804.
  26. Krugers HJ, Koolhaas JM, Bohus B, Korf J: A single social stress-experience alters glutamate receptor-binding in rat hippocampal CA3 area. Neurosci Lett 1993;154:73–77.
  27. Jezova D, Jurankova E, Vigas M: Glutamate neurotransmission, stress and hormone secretion. Bratisl Lek Listy 1995;96:588–596.
  28. Schoepp DD, Wright RA, Levine LR, Gaydos B, Potter WZ: LY354740, an mGlu2/3 receptor agonist, as a novel approach to treat anxiety/stress. Stress 2003;6:189–197.

    External Resources

  29. Carlson HE, Miglietta JT, Roginsky MS, Stegink LD: Stimulation of pituitary hormone secretion by neurotransmitter amino acids in humans. Metabolism 1989;38:1179–1182.
  30. Fernstrom JD: Pituitary hormone secretion in normal male humans: Acute responses to a large, oral dose of monosodium glutamate. J Nutr 2000;130:1053S–1057S.
  31. Tena-Sempere M, Pinilla L, Gonzalez LC, Aguilar E: Regulation of growth hormone secretion by different glutamate receptor subtypes in the rat. Amino Acids 2000;18:1–16.
  32. Pinilla L, Gonzalez LC, Tena-Sempere M, Aguilar E: Cross-talk between excitatory and inhibitory amino acids in the regulation of growth hormone secretion in neonatal rats. Neuroendocrinology 2001;73:62–67.
  33. Pinilla L, Barreiro ML, Tena-Sempere M, Aguilar E: Role of ghrelin in the control of growth hormone secretion in prepubertal rats: Interactions with excitatory amino acids. Neuroendocrinology 2003;77:83–90.
  34. Ramsay RE, Pellock JM, Garnett WR, Sanchez RM, Valakas AM, Wargin WA, Lai AA, Hubbell J, Chern WH, Allsup T: Pharmacokinetics and safety of lamotrigine (Lamictal) in patients with epilepsy. Epilepsy Res 1991;10:191–200.
  35. Clamage DM, Vander AJ, Mouw DR: Psychosocial stimuli and human plasma renin activity. Psychosom Med 1977;39:393–401.
  36. Kosunen KJ: Plasma renin activity, angiotensin II, and aldosterone after mental arithmetic. Scand J Clin Lab Invest 1977;37:425–429.
  37. Broughton PF, Waldron BA: Ketamine hypertension and the renin-angiotensin system. Clin Exp Hypertens A 1983;5:875–883.
  38. Haller J, Makara GB, Kruk MR: Catecholaminergic involvement in the control of aggression: Hormones, the peripheral sympathetic, and central noradrenergic systems. Neurosci Biobehav Rev 1998;22:85–97.
  39. Sapolsky RM, Romero LM, Munck AU: How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory and preparative actions. Endocr Rev 2000;21:55–89.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50